MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.3690
+0.0090
+2.50%
After Hours: 0.3690 0 0.00% 17:29 07/10 EDT
OPEN
0.3690
PREV CLOSE
0.3600
HIGH
0.3800
LOW
0.3600
VOLUME
7.14M
TURNOVER
--
52 WEEK HIGH
0.6200
52 WEEK LOW
0.1570
MARKET CAP
145.81M
P/E (TTM)
-2.7476
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATNM stock price target is 2.750 with a high estimate of 4.000 and a low estimate of 1.500.

EPS

ATNM News

More
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
Zacks · 1d ago
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Zacks · 2d ago
81 Biggest Movers From Yesterday
Gainers Electrameccanica Vehicles Corp. (NASDAQ: SOLO) climbed 64.5% to close at $5.15 on Monday after jumping more than 34% on Thursday.
Benzinga · 3d ago
62 Stocks Moving In Monday's Mid-Day Session
Gainers Ayro, Inc. (NASDAQ: AYRO) shares jumped 105.8% to $6.73 after the company completed its factory expansion that will allow it to handle up to 600 EVs per month, compared to only 200 per month before the expansion.
Benzinga · 4d ago
35 Stocks Moving in Monday's Pre-Market Session
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares rose 88.2% to $2.39 in pre-market trading after declining over 5% on Thursday.
Benzinga · 4d ago
Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering
PR Newswire · 06/19 22:15
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Zacks · 06/17 16:30
Actinium Pharmaceuticals Prices 76.9M Share Public Offering of Common Stock @$0.325/Share
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) y announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock
Benzinga · 06/17 09:40

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About ATNM

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
More

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.